AltruBio (formerly AbGenomics) is a biopharmaceutical company focused on developing antibody therapeutics for the treatment of cancer and immune-related inflammatory diseases. It builds a discovery platform to identify and validate antibody therapeutics. The company develops an immune checkpoint agonist antibody, a gastrointestinal (GI) tumor-selective antigen, and a linker for antibody-drug conjugate products. Its drug candidates designed for treating T Cell mediated diseases and GI oncological diseases.